IBERSOL SGPS SA (IBS.LS) Stock Fundamental Analysis

ELI:IBS • PTIBS0AM0008

11.3 EUR
+0.05 (+0.44%)
Last: Feb 16, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

IBS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 61 industry peers in the Hotels, Restaurants & Leisure industry. IBS has only an average score on both its financial health and profitability. IBS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year IBS was profitable.
  • In the past year IBS had a positive cash flow from operations.
  • IBS had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years IBS had a positive operating cash flow.
IBS.LS Yearly Net Income VS EBIT VS OCF VS FCFIBS.LS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 1.91%, IBS is doing worse than 60.66% of the companies in the same industry.
  • IBS's Return On Equity of 4.21% is in line compared to the rest of the industry. IBS outperforms 55.74% of its industry peers.
  • The Return On Invested Capital of IBS (4.53%) is comparable to the rest of the industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for IBS is significantly below the industry average of 11.93%.
  • The last Return On Invested Capital (4.53%) for IBS is above the 3 year average (3.32%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.91%
ROE 4.21%
ROIC 4.53%
ROA(3y)9.49%
ROA(5y)5.17%
ROE(3y)16.68%
ROE(5y)5.68%
ROIC(3y)3.32%
ROIC(5y)N/A
IBS.LS Yearly ROA, ROE, ROICIBS.LS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

  • The Profit Margin of IBS (2.56%) is comparable to the rest of the industry.
  • IBS's Profit Margin has declined in the last couple of years.
  • IBS has a Operating Margin (5.83%) which is comparable to the rest of the industry.
  • IBS's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 52.62%, IBS is in the better half of the industry, outperforming 60.66% of the companies in the same industry.
  • IBS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 5.83%
PM (TTM) 2.56%
GM 52.62%
OM growth 3Y-40.02%
OM growth 5Y-6.76%
PM growth 3Y-42.54%
PM growth 5Y-4.22%
GM growth 3Y-0.29%
GM growth 5Y-0.28%
IBS.LS Yearly Profit, Operating, Gross MarginsIBS.LS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IBS is destroying value.
  • IBS has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for IBS has been increased compared to 5 years ago.
  • Compared to 1 year ago, IBS has a worse debt to assets ratio.
IBS.LS Yearly Shares OutstandingIBS.LS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
IBS.LS Yearly Total Debt VS Total AssetsIBS.LS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • IBS has an Altman-Z score of 2.17. This is not the best score and indicates that IBS is in the grey zone with still only limited risk for bankruptcy at the moment.
  • IBS has a better Altman-Z score (2.17) than 60.66% of its industry peers.
  • IBS has a debt to FCF ratio of 3.47. This is a good value and a sign of high solvency as IBS would need 3.47 years to pay back of all of its debts.
  • IBS's Debt to FCF ratio of 3.47 is fine compared to the rest of the industry. IBS outperforms 70.49% of its industry peers.
  • A Debt/Equity ratio of 0.66 indicates that IBS is somewhat dependend on debt financing.
  • IBS has a Debt to Equity ratio of 0.66. This is in the better half of the industry: IBS outperforms 72.13% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 3.47
Altman-Z 2.17
ROIC/WACC0.72
WACC6.3%
IBS.LS Yearly LT Debt VS Equity VS FCFIBS.LS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • IBS has a Current Ratio of 1.02. This is a normal value and indicates that IBS is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.02, IBS is in the better half of the industry, outperforming 62.30% of the companies in the same industry.
  • IBS has a Quick Ratio of 1.02. This is a bad value and indicates that IBS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of IBS (0.92) is better than 60.66% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.92
IBS.LS Yearly Current Assets VS Current LiabilitesIBS.LS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for IBS have decreased strongly by -16.66% in the last year.
  • Measured over the past years, IBS shows a decrease in Earnings Per Share. The EPS has been decreasing by -8.23% on average per year.
  • The Revenue has grown by 15.02% in the past year. This is quite good.
  • Measured over the past years, IBS shows a decrease in Revenue. The Revenue has been decreasing by -0.46% on average per year.
EPS 1Y (TTM)-16.66%
EPS 3Y-29.2%
EPS 5Y-8.23%
EPS Q2Q%83.33%
Revenue 1Y (TTM)15.02%
Revenue growth 3Y32.48%
Revenue growth 5Y-0.46%
Sales Q2Q%7.53%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.57% on average over the next years. This is quite good.
  • Based on estimates for the next years, IBS will show a small growth in Revenue. The Revenue will grow by 7.42% on average per year.
EPS Next Y-38.06%
EPS Next 2Y-0.66%
EPS Next 3Y2.31%
EPS Next 5Y17.57%
Revenue Next Year15.95%
Revenue Next 2Y10.49%
Revenue Next 3Y8.64%
Revenue Next 5Y7.42%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBS.LS Yearly Revenue VS EstimatesIBS.LS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M
IBS.LS Yearly EPS VS EstimatesIBS.LS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • IBS is valuated quite expensively with a Price/Earnings ratio of 33.24.
  • Compared to the rest of the industry, the Price/Earnings ratio of IBS is on the same level as its industry peers.
  • When comparing the Price/Earnings ratio of IBS to the average of the S&P500 Index (27.19), we can say IBS is valued slightly more expensively.
  • Based on the Price/Forward Earnings ratio of 35.71, the valuation of IBS can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of IBS is on the same level as its industry peers.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. IBS is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 33.24
Fwd PE 35.71
IBS.LS Price Earnings VS Forward Price EarningsIBS.LS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, IBS is valued cheaply inside the industry as 85.25% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 5.58
EV/EBITDA N/A
IBS.LS Per share dataIBS.LS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.66%
EPS Next 3Y2.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • IBS has a Yearly Dividend Yield of 6.28%, which is a nice return.
  • Compared to an average industry Dividend Yield of 1.38, IBS pays a better dividend. On top of this IBS pays more dividend than 98.36% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, IBS pays a better dividend.
Industry RankSector Rank
Dividend Yield 6.28%

5.2 History

  • On average, the dividend of IBS grows each year by 48.65%, which is quite nice.
Dividend Growth(5Y)48.65%
Div Incr Years0
Div Non Decr Years0
IBS.LS Yearly Dividends per shareIBS.LS Yearly Dividends per shareYearly Dividends per share 2019 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • 213.50% of the earnings are spent on dividend by IBS. This is not a sustainable payout ratio.
  • IBS's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP213.5%
EPS Next 2Y-0.66%
EPS Next 3Y2.31%
IBS.LS Yearly Income VS Free CF VS DividendIBS.LS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M
IBS.LS Dividend Payout.IBS.LS Dividend Payout, showing the Payout Ratio.IBS.LS Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

IBERSOL SGPS SA

ELI:IBS (2/16/2026, 7:00:00 PM)

11.3

+0.05 (+0.44%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)11-27
Earnings (Next)04-27
Inst Owners21.87%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap462.17M
Revenue(TTM)522.73M
Net Income(TTM)13.37M
Analysts83.33
Price Target11.92 (5.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.28%
Yearly Dividend0.49
Dividend Growth(5Y)48.65%
DP213.5%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-3.41%
Max Revenue beat(2)-0.81%
Revenue beat(4)2
Avg Revenue beat(4)4.87%
Min Revenue beat(4)-3.41%
Max Revenue beat(4)12.41%
Revenue beat(8)6
Avg Revenue beat(8)5.92%
Revenue beat(12)8
Avg Revenue beat(12)5.42%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-16.31%
EPS NY rev (3m)-25.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
Industry RankSector Rank
PE 33.24
Fwd PE 35.71
P/S 0.88
P/FCF 5.58
P/OCF 3.59
P/B 1.46
P/tB 2.11
EV/EBITDA N/A
EPS(TTM)0.34
EY3.01%
EPS(NY)0.32
Fwd EY2.8%
FCF(TTM)2.02
FCFY17.91%
OCF(TTM)3.15
OCFY27.84%
SpS12.78
BVpS7.76
TBVpS5.36
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.7
Profitability
Industry RankSector Rank
ROA 1.91%
ROE 4.21%
ROCE 5.74%
ROIC 4.53%
ROICexc 5.96%
ROICexgc 7.87%
OM 5.83%
PM (TTM) 2.56%
GM 52.62%
FCFM 15.84%
ROA(3y)9.49%
ROA(5y)5.17%
ROE(3y)16.68%
ROE(5y)5.68%
ROIC(3y)3.32%
ROIC(5y)N/A
ROICexc(3y)5.24%
ROICexc(5y)N/A
ROICexgc(3y)7.05%
ROICexgc(5y)N/A
ROCE(3y)4.21%
ROCE(5y)N/A
ROICexgc growth 3Y-24.94%
ROICexgc growth 5Y-3.32%
ROICexc growth 3Y-22.88%
ROICexc growth 5Y-3.24%
OM growth 3Y-40.02%
OM growth 5Y-6.76%
PM growth 3Y-42.54%
PM growth 5Y-4.22%
GM growth 3Y-0.29%
GM growth 5Y-0.28%
F-Score7
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 3.47
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 8.77%
Interest Coverage 250
Cash Conversion N/A
Profit Quality 619.36%
Current Ratio 1.02
Quick Ratio 0.92
Altman-Z 2.17
F-Score7
WACC6.3%
ROIC/WACC0.72
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)9.76%
Cap/Sales(5y)11.65%
Profit Quality(3y)200.89%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.66%
EPS 3Y-29.2%
EPS 5Y-8.23%
EPS Q2Q%83.33%
EPS Next Y-38.06%
EPS Next 2Y-0.66%
EPS Next 3Y2.31%
EPS Next 5Y17.57%
Revenue 1Y (TTM)15.02%
Revenue growth 3Y32.48%
Revenue growth 5Y-0.46%
Sales Q2Q%7.53%
Revenue Next Year15.95%
Revenue Next 2Y10.49%
Revenue Next 3Y8.64%
Revenue Next 5Y7.42%
EBIT growth 1Y34.45%
EBIT growth 3Y-20.54%
EBIT growth 5Y-7.19%
EBIT Next Year455.28%
EBIT Next 3Y83.41%
EBIT Next 5Y61.42%
FCF growth 1Y88.1%
FCF growth 3Y-0.14%
FCF growth 5Y-9.32%
OCF growth 1Y61.81%
OCF growth 3Y1.82%
OCF growth 5Y-6.35%

IBERSOL SGPS SA / IBS.LS FAQ

What is the ChartMill fundamental rating of IBERSOL SGPS SA (IBS.LS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to IBS.LS.


Can you provide the valuation status for IBERSOL SGPS SA?

ChartMill assigns a valuation rating of 2 / 10 to IBERSOL SGPS SA (IBS.LS). This can be considered as Overvalued.


Can you provide the profitability details for IBERSOL SGPS SA?

IBERSOL SGPS SA (IBS.LS) has a profitability rating of 4 / 10.


What is the financial health of IBERSOL SGPS SA (IBS.LS) stock?

The financial health rating of IBERSOL SGPS SA (IBS.LS) is 4 / 10.


Can you provide the dividend sustainability for IBS stock?

The dividend rating of IBERSOL SGPS SA (IBS.LS) is 6 / 10 and the dividend payout ratio is 213.5%.